<DOC>
	<DOCNO>NCT00901342</DOCNO>
	<brief_summary>This Multicenter , Open Label , Phase 2 Study Sipuleucel-T Men Metastatic Castrate Resistant Prostate Cancer ( CRPC ) .</brief_summary>
	<brief_title>Open Label Study Sipuleucel-T</brief_title>
	<detailed_description>Subjects receive investigational product , sipuleucel-T , approximately 2-week interval , total 3 infusion . The study evaluate safety magnitude immune response treatment sipuleucel-T. All subject follow 30 day follow last infusion sipuleucel-T . The study also available placebo subject participate D9902B study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>For subject eligible participation study , follow criterion must satisfy . Histologically document adenocarcinoma prostate . Metastatic disease . Castrate resistant prostate cancer . Castrate level testosterone ( &lt; 50 ng/dL ) achieve via medical surgical castration . Life expectancy least 3 month . Men &gt; = 18 year age . Adequate hematologic , renal liver function . A subject eligible participation study follow criterion apply . The presence know lung , liver , brain metastasis . Evidence neuroendocrine small cell feature . Eastern Cooperative Oncology Group ( ECOG ) performance status &gt; 2 . Prior treatment 3 infusion sipuleucelT ( infusion APC8015F exclusionary ) Imminent pathologic longbone fracture ( cortical erosion radiography &gt; 50 % ) spinal cord compression . Known malignancy prostate cancer likely require treatment within six month registration . A requirement systemic immunosuppressive therapy reason . A history allergic reaction attribute compound similar chemical biologic composition sipuleucelT GMCSF . Any infection require parenteral antibiotic therapy cause fever ( temp &gt; 100.5F &gt; 38.1C ) within 1 week prior registration . Any medical intervention condition , opinion Principal Investigator Dendreon Medical Monitor , could compromise adherence study requirement otherwise compromise study 's objective . Treatment follow medication intervention within 28 day registration : Systemic corticosteroid . Use inhale , intranasal , intraarticular , topical steroid acceptable , short course ( ie , ≤ 1 day ) corticosteroid prevent reaction IV contrast use CT scan . Nonsteroidal antiandrogens ( eg , bicalutamide , flutamide , nilutamide ) . External beam radiation therapy major surgery require general anesthetic . Any systemic therapy prostate cancer include secondary hormonal therapy , megestrol acetate ( Megace® ) , diethylstilbestrol ( DES ) , ketoconazole . Medical castration therapy exclusionary . Chemotherapy . Treatment investigational product .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>AIPC</keyword>
	<keyword>CRPC</keyword>
	<keyword>prostate cancer</keyword>
	<keyword>prostate</keyword>
	<keyword>immune therapy</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>vaccine</keyword>
	<keyword>dendritic cell</keyword>
	<keyword>antigen-presenting cell</keyword>
	<keyword>antigen present cell</keyword>
	<keyword>cancer vaccine</keyword>
	<keyword>PSA</keyword>
	<keyword>prostatic adenocarcinoma</keyword>
</DOC>